Sponsored by:

Molecular Imaging: Page 71

Week in Review: Virtual conference March 30-31 | New prostate treatment | COVID and cancer screening
By Brian Casey
March 25, 2022
ITM promotes supply deal with Novartis for Pluvicto
By AuntMinnie.com staff writers
German radiopharmaceutical firm ITM Isotope Technologies Munich SE (ITM) highlighted its lutetium-177 supply deal with Novartis in the wake of the U.S. Food and Drug Administration's approval of the company's Pluvicto radioligand therapy.
March 24, 2022
2018 12 11 00 02 7009 Atom Nuclear Lab 400
PET reveals visual brain pattern of long COVID
By Will Morton
Nuclear medicine physicians in France have identified a metabolic pattern on brain PET images that indicates the presence of long COVID-19 in patients, according to a study published March 23 in the European Journal of Nuclear Medicine and Molecular Imaging.
March 24, 2022
2022 03 24 22 39 9690 2022 03 25 Long Covid On Pet 20220324223059
PET improves prostate cancer survival predictions
By Will Morton
Prostate cancer PET scans can help predict how long patients may survive disease-free after radical prostatectomy, according to a study published March 17 in the European Journal of Nuclear Medicine and Molecular Imaging.
March 24, 2022
2021 01 16 00 14 5464 Prostate Cancer 400
Clarity launching trial for prostate cancer therapy
By AuntMinnie.com staff writers
Clarity Pharmaceuticals is launching an investigator-initiated trial that will focus on the use of its copper-64 (Cu-64)-labeled radiopharmaceutical, Cu-64 SAR-bisPSMA, in prostate cancer.
March 23, 2022
2020 07 15 23 29 3710 Cancer Cells Prostate 400
FDA approves Lu-177 PSMA-617 for prostate cancer treatment
By Will Morton
The U.S. Food and Drug Administration (FDA) has approved lutetium-177 (Lu-177) prostate-specific membrane antigen radioligand therapy for the treatment of patients with metastatic prostate cancer.
March 22, 2022
2019 02 13 19 24 5396 Fda Logo V2 400
Eckert & Ziegler partners with Alpha-9 Theranostics
By AuntMinnie.com staff writers
Isotope technology firm Eckert & Ziegler has agreed to supply lutetium-177 to the Canadian biotechnology firm Alpha-9 Theranostics for use in clinical trials.
March 22, 2022
2019 12 19 00 53 5252 Hands Shaking Deal 400
Navidea reports revenue declines in Q4, all of 2021
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals reported a decline in revenues for the fourth quarter of 2021 and the entire year.
March 22, 2022
2017 04 03 18 01 52 418 Graph Arrow Down 400
Sysmex, Eisai highlight Alzheimer's research at AD/PD 2022
By AuntMinnie.com staff writers
Sysmex and Eisai shared research from their joint effort to create a diagnostic blood test for Alzheimer's disease at this week's International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) in Barcelona, Spain.
March 22, 2022
2017 04 14 16 09 55 745 Amyloid Plaque Alzheimer 400
MedTrace Pharma prepares phase III trial for O-15 PET
By AuntMinnie.com staff writers
Danish PET technology developer MedTrace Pharma has received an investigational new drug exemption from the U.S. Food and Drug Administration, paving the way for a clinical trial to assess the firm's radioactive water (oxygen-15 water) PET imaging technique in detecting coronary artery disease.
March 21, 2022
2017 02 10 15 45 57 410 Heart 400
ITM secures new investment to spur development
By AuntMinnie.com staff writers
German radiopharmaceutical firm ITM Isotope Technologies Munich has raised 33 million euros ($36.4 million U.S.) in another new equity investment.
March 21, 2022
2020 04 20 23 13 8684 Euros Bills 400
NaF-PET reveals aortic wall injuries
By Will Morton
PET imaging with F-18 sodium fluoride (NaF) can detect activity related to tears in the outer wall of the aorta and could help manage patients with acute aortic syndrome, according to a study published March 16 in JACC: Cardiovascular Imaging.
March 21, 2022
2022 03 21 23 32 8561 2022 03 22 Pet Aortic Syndrome 20220321235334
Previous Page
Page 71 of 611
Next Page